These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 12750278)

  • 1. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
    Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
    J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
    Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
    Vinay DS; Kwon BS
    Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28.
    Hurtado JC; Kim SH; Pollok KE; Lee ZH; Kwon BS
    J Immunol; 1995 Oct; 155(7):3360-7. PubMed ID: 7561030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
    Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4.
    Pollok KE; Kim SH; Kwon BS
    Eur J Immunol; 1995 Feb; 25(2):488-94. PubMed ID: 7875212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
    Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costimulation of CD28- T lymphocytes by 4-1BB ligand.
    DeBenedette MA; Shahinian A; Mak TW; Watts TH
    J Immunol; 1997 Jan; 158(2):551-9. PubMed ID: 8992967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death.
    Hurtado JC; Kim YJ; Kwon BS
    J Immunol; 1997 Mar; 158(6):2600-9. PubMed ID: 9058792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.
    Li Q; Furman SA; Bradford CR; Chang AE
    Clin Cancer Res; 1999 Feb; 5(2):461-9. PubMed ID: 10037198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
    Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
    Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB.
    Cannons JL; Hoeflich KP; Woodgett JR; Watts TH
    J Immunol; 1999 Sep; 163(6):2990-8. PubMed ID: 10477561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
    Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.